secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0000318154-25-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen Q1 beats: revenue $8.1B (+9%), non-GAAP EPS $4.90 (+24%), FCF $1.0B
-------------------------------------------------------------------------

- GAAP EPS $3.20 vs -$0.21; includes $800M Otezla intangible impairment.
- Non-GAAP EPS $4.90 (+24% YoY) on revenue $8.1B (+9%).
- Product sales up 11% with 14% volume growth; 14 products had double-digit growth.
- Free cash flow $1.0B vs $0.5B prior year, driven by business performance.
- IMDELLTRA sales $81M; Phase 3 confirmatory trial improved overall survival vs chemo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000031815425000018/0000318154-25-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000031815425000018/amgn-20250501.htm
  HTML page:      https://secwatch.observer/filing/0000318154-25-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer